Grantham, Mayo, Van Otterloo & Co (GMO)
NBIX icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Neurocrine Biosciences NBIX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.69M Buy
35,626
+28,493
+399% +$3.78M 0.01% 334
2025
Q4 		$1.01M Buy
+7,133
New +$1.03M ﹤0.01% 517

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s NBIX Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) increased its Neurocrine Biosciences (NBIX) stake by 399% in Q1 2026, buying an estimated $3.78M and bringing the position to 35,626 shares worth $4.69M. The position accounts for 0.01% of the portfolio, ranked #334.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in NBIX in Q4 2025 and has held it in 2 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 35,626 shares of Neurocrine Biosciences worth $4.69M as of Q1 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) bought 28,493 Neurocrine Biosciences shares in Q1 2026, an estimated $3.78M.
  • Neurocrine Biosciences made up 0.01% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #334 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 2 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.